Garnet E. Peck, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Garnet E. Peck, PhD


Garnet E. Peck, PhD
Professor Emeritus of
Industrial Pharmacy
Purdue University

Garnet E. Peck is a professor emeritus and visiting professor in the department of industrial and physical pharmacy at Purdue University’s School of Pharmacy and Pharmaceutical Sciences. He received his BS (1957) in pharmacy from Ohio Northern University and MS (1959) and PhD (1962) degrees in industrial pharmacy from Purdue University. From 1962 to 1967, Peck was employed by the Mead Johnson Research Center and in 1967 he returned to Purdue University to join the department of industrial and physical pharmacy.  He was associate department head from 1989 to 1996.

Peck’s research interests include optimization of drug product design and process design, in particular those systems involving tablets, topical drug ad­sorption, flow of solid systems, dispersed systems design and evaluation, new tablet coating materials and procedures, and excipient-drug interaction. His research has resulted in more than 110 scientific publications.

Peck is a member of the APhA, the PT Section of the American Association of Pharmaceutical Scientists (AAPS), ACS, AACP, New York Academy of Science, Sigma Xi, Rho Chi, Phi Lambda Upsilon, Phi Kappa Phi and is a fellow of the AAAS, APRS, AAPS, and the American Institute of Chemists.  Peck was chairman of the IPT Section of the Academy of Pharmaceutical Sciences for 1983-84.  He was elected to the 1985-1990 United States Pharmacopeia Committee of Revision and then re-elected to the committee for 1990-1995 and 1995-2000. He was elected to the Committee of Experts, Excipients for 2000-2005. Peck is a founding member of The Catholic Academy of Science in the United States founded in 1987.

In March 1994, he was awarded by the American Pharmaceutical Association the Sidney L. Riegelman Research Achievement Award in Pharmaceutics, and he received the Pharmaceutical Technology Publishers’ Award in September 1994.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here